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Introduction
Three tragedies mark the use of radiation to treat brain
tumours in children. The most obvious is the injustice of
fate that forces such young patients to suffer such serious
disease. The second tragedy is that brain tumours of
childhood tend to have malignant courses and act more
aggressively than their counterparts in adults. They are
also the most common solid tumours of childhood [1, 2].
The third tragedy is the frustrating fact that what would
otherwise be a valuable mainstay of treatment, radiation
therapy, is virtually forbidden in young children because
of the high risk of devastating cognitive deficits in later
life [1, 3-6]. This has produced the common strategy of
restricting the treatment of young children to chemo-
therapy and surgery, hoping to delay until the child is
older and the brain better able to withstand radiation.
Nevertheless, paediatric oncologists can find themselves
facing very aggressive brain tumours in very young
patients without a full complement of therapeutic tools.
The possibility that stereotactic radiosurgery (SRS)
might restore the use of radiation to the treatment
armamentarium is not new and has not been overlooked
by the oncology community. Because little radiation is
delivered by SRS treatment plans to normal tissue outside
the treatment field, the risk of damage to eloquent cortex
and the accompanying decline in cognitive function
should be vanishingly small. This realisation has prompted
a large number of paediatric centres to incorporate SRS
into their treatment strategies [7-27].
Many radiosurgery centres have chosen frame-based
systems such as the Gamma Knife to treat paediatric
tumours, perhaps motivated by the stringent requirements
of SRS for precision. Treatment of infants is prohibited
with this method because the fragile infant skull cannot
withstand placement of a stereotactic frame required for
rigid fixation. Furthermore, rigid fixation in children
requires general anaesthesia with its attendant problems
of vomiting, tube obstruction and post-extubation croup.
These are magnified by the limited airway access imposed
by the rigid frame [16, 28]. That such problems can be
significant has been shown by a report in 1995 [29] of
four serious anaesthetic events in 68 frame-based SRS
procedures for children.
A proposed solution to these problems is the use of
non-invasive devices to immobilise the head during SRS.
However, devices relying on fixation to the teeth with
a dental mould (such as the Greitz-Bergstrom method
or the Gill-Thomas-Cosman frame) are unsuitable for
infants and for children requiring general anaesthesia
[30, 31]. Devices such as the Laitinen stereoadapter have
been widely used for adults but the effect of this tight
device on the pliable infant skull is uncertain and errors
have been reported as large as 3.75 mm [32, 33]. Even the
Boston children’s frame, which uses customised occipital
and chin moulds to successfully deliver SRS to high doses
using a small number of fractions, is not advocated for
single-shot SRS because of associated errors as large as
several millimetres [34].
What is needed for effective SRS for children is
therefore almost precisely what the CyberKnife has
to offer: a frameless delivery system with accuracy
approaching that of frame-based SRS [35, 36]. This theory
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has been translated to practice, the feasibility of
CyberKnife SRS for infants has been proven [37] and the
initial clinical experience in a group of paediatric patients
with brain tumours has been reported [38]. 
Patient selection 
Appropriate selection of children for SRS is similar to
the selection process for adults. The tumour must have
a focal component amenable to SRS targeting and must
not be so large that effective doses are prevented. The
longevity and overall performance status of the patient
should be assessed as should any reasonable expectations
of treatment efficacy or failure. 
We believe that the special characteristics of
paediatric illness require that SRS decisions be made in
the context of a paediatric tumor board consisting of
a full complement of paediatric specialists: including
paediatric oncologists, neurosurgeons, radiation oncolo-
gists, pathologists, neurologists and social workers. The
advantage of this approach is that all the nuances of
treatment peculiar to the paediatric patient can be
considered at once, including aspects of pathology and
clinical response particular to children. Moreover, such
groups are often the only access to paediatric clinical
trials and the best access to the specific social and
psychological support so essential to the family of a child
with a brain tumour. Given the complexity of paediatric
patients and the variety of treatment options available in
a children’s hospital, the overall goal should be to
incorporate SRS as part of a comprehensive treatment
strategy rather than as a stand-alone tool. 
Parents and consent
The discussion and consent process for SRS should be
modelled on that for conventional surgery, including frank
discussions with the parents or guardians and an
explanation to the patient that is appropriate for age and
sensitive to the child’s ability to understand these serious
issues. The risk of radiation induced malignancy is
particularly relevant for young patients and should be
included in the adult portion of the informed consent.
‘Kid friendly’ touches such as children’s books and
posters, music, toys and a receptive staff are appreciated
tremendously by patients and even more by parents.
Anaesthesia
The delivery of CyberKnife SRS to an older child is
virtually identical to that for an adult, but there are
important differences when the patient is an infant or
young child. Because rigid head fixation is not required
for CyberKnife SRS, most adults are quite comfortable
during the procedure and general anaesthesia is not
needed. The same is true for older children and
occasionally for a young child. We have seen completely
uneventful treatments without anaesthesia for children
as young as five years old. However, even the superb
tracking abilities of the CyberKnife system are no match
for a squalling infant, therefore general anaesthesia
should be available for babies and younger children.
Anaesthesia adds to the risk and complexity of the
procedure and must be thoroughly discussed with the
parents as part of the consent process.
Because most SRS suites are relatively far from the
surgical areas of the hospital, it is important to carefully
plan how the patient will be transported. Some centres
induce anaesthesia in a remote area, transport the patient
to the CyberKnife suite, and bring the patient back to
the anaesthesia department for recovery after treatment.
Other centres induce anaesthesia in the CyberKnife suite
with the patient recovering elsewhere. In either case, the
transportation route and the roles of each member of
the team must be rehearsed to avoid accidents.
Other anaesthetic issues are also relevant for
children. Some arise because the anaesthesiologist cannot
remain with the patient during treatment. These include
the need to carefully monitor the temperature of these
small patients within the relatively cold SRS vault, to
monitor physiological variables during treatment by using
a videocamera or a direct link, and to establish a protocol
for rapid access to the patient if this is needed during
treatment. Another anaesthesia issue is that of hyper-
ventilation and diuresis. We prefer that physiological
variables such as end tidal CO2 and volume be kept as
constant as possible during imaging and treatment. This is
to ensure that the brain does not move in a way that
would corrupt the stereotactic targeting. 
Anaesthesia for paediatric SRS poses unique pro-
blems for neurologically ill young patients: remote access
during the procedure and the necessity for transportation.
We also believe that it is a task best suited for anaesthe-
siologists with paediatric skills and credentials.
Immobilisation
Immobilisation during imaging and treatment for older
children is identical to that for adults in which a custom-
made mask immobilises the head and neck. For children
requiring general anaesthesia, the mask can be made to
accommodate the endotrachial tube without compromi-
sing immobilisation [37]. However, problems arise for
younger children because their heads are large in com-
parison to their bodies. This means that flexibility can
defeat a head mask alone. We have found that effective
immobilisation can be achieved in these cases by using
a VacLok bag to immobilise the body and attaching it to
the mask and a supporting Timo headrest (Figure 1) [37].
Imaging and tracking
The CT images which are used for treatment and the
MR images which are used for tumour evaluation should
be obtained with contrast even if intravenous access is
technically difficult. For young children with small heads
and subtle anatomy, we have found the use of thin
sections and image fusion to be helpful. Attenuation of
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the kilovoltage used to obtain the treatment radiographs
and CT scans for planning may be necessary to track the
thin skulls of younger patients.
Dose magnitude
Although many centres have found that the radiation
doses accepted for adult radiosurgery are also appropriate
for older children [7-14] there are only a few reports on
doses for single-shot SRS for infants and younger
children. During our early experiences, we reduced our
doses from those suitable for adults by about 25%
because of the lack of guidance in the literature and
concern about the fragility of the young brain. Then,
because of a poor response observed in several of our
patients treated with these doses, and also encouraged
by a low rate of radiation necrosis [37, 38], we became
more aggressive so that our current strategies are similar
to those for adult radiosurgery. 
This philosophy is in agreement with that of Smyth et
al [39] who believe that their relatively low rate of success
for the treatment of arteriovenous malformations (AVMs)
was due to conservative dose prescriptions and with
Tanaka et al [40] who reported better results in children
than in adults with AVMs when using similar doses. Based
on this admittedly anecdotal experience we consider that
the paediatric brain is only slightly more susceptible to
radiation induced oedema and necrosis than the adult
brain.
Hypofractionation
Brain tumours of childhood are often large and frequently
located in the posterior fossa or other sensitive areas such
as those adjacent to the optic apparatus. Moreover, many
children referred for SRS have already received and failed
conventional radiotherapy. Because these factors increase
the risk of radiation induced injury when single-shot SRS
is chosen, we frequently consider a hypofractionated
regimen in which the dose is delivered over several days
instead of all at once. Nevertheless, the theory that
the use of SRS with a small number of fractions will retain
the efficacy of single-shot SRS and at the same time enjoy
the safety of conventional fractionation although
appealing is unproven and the optimal parameters of
hypofractionation (total and daily dose) are unclear. 
During our early experience, our hypofractionation
regimens were conservative (for example, a total dose
of 15 Gy delivered in five daily fractions), but encouraged
by a lack of radionecrosis and motivated by tumour
recurrence, we now use a regimen of 20-25 Gy delivered
in 4-5 daily fractions. Such a hypofractionated regimen
was used in eight of our 38 treatments (21%) without
any difficulties related to the need for daily anaesthesia
[38]. We believe that hypofractionated regimens made
available by the frameless CyberKnife SRS technique will
continue to be useful clinical tools.
Patient population
A total of 38 radiosurgical treatments were delivered to 21
paediatric patients (8/21 male and 13/21 female) with
ages ranging from 8 months to 16 years with a mean age
of 7.0 years and a median age of 6.0 years at the time of
their first CyberKnife SRS treatment (Table I). There
were three patients with pilocytic astrocytomas, two with
anaplastic astrocytomas, three with ependymomas (two
anaplastic), four with medulloblastomas, one with
a primitive neuroectodermal tumour (PNET), three with
craniopharyngiomas, three with atypical teratoid-rhabdoid
tumors, one with a pineoblastoma and one with a me-
ningioma. Also, 10/21 had previously received external
beam radiotherapy to the regions ultimately treated with
SRS. The mean time lapse between radiotherapy and
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Figure 1. Schematic drawing of the CyberKnife SRS method for infants. In some cases a face mask is used (top left inset). D denotes the X-ray
detector. (This figure and portions of Figures 2, 3 and 4 are used with permission and appear in Giller CA et al. Feasibility of radiosurgery for
malignant brain tumors in infants: preliminary report. Neurosurgery 2004; 55: 916-925) 
SRS was 2.6 years ± 2.2 years. Chemotherapy had been
administered to 16/21, 20/21 had received resective
surgery, and 12/21 had undergone two or more surgical
procedures. In addition, 14/21 had been treated for
residual tumour following surgery and 4/21 had been
treated for recurrent tumour.
Table I. Age distribution of our 21 patients treated 
using CyberKnife SRS at the University 
of Texas Southwestern Medical Center in Dallas [37, 28]
Age range Number of
(years) patients
≤ 3 6
4-6 6
7-9 2
10-12 3
13-16 4
SRS treatment characteristics
The mean number of treatments per patient was 1.8
(range 1-7) with 7/21 receiving more than one SRS
treatment and 6/21 receiving SRS to more than one
lesion. The mean target volume was 10.7 cm3 (range 0.06-
103 cm3), the mean number of paths was 2.4 and the
mean number of beams 127. The mean dose at the
margin was 18.8 Gy (range 9.2-50 Gy and median of
17 Gy) and the mean marginal isodose line was 57%
(range 35-90% and median of 60%). A total of 27/38 of
the SRS treatments were delivered using a single dose
and 8/38 using 3-5 fractions. The three patients with
craniopharyngiomas were treated with a conventional
fractionation schedule.
Results 
Our most recent results are given in Table II. The mean
follow-up period is 18 months (range 1-40 months). For
the 15/21 patients still alive, the mean follow-up is 21
months (range 1-40 months). The time between the initial
CyberKnife SRS treatment and death for the 6/21 patients
who died, was 10 months (range 6-16 months).
There were no deaths or complications related to
the procedures, although there was 29% (6/21) mortality
during the periods of currently available follow-up.
Symptomatic radionecrosis was seen in only one patient
who had been heavily treated for a recurrent atypical
teratoid-rhabdoid tumour. Asymptomatic radionecrosis
was noted in a further two patients. 
As an example case history, a one-year old boy
suffered a posterior fossa haemorrhage and a biopsy
obtained during evacuation showed a low grade glioma.
It was elected to observe him but the tumour grew
six months later, and a second biopsy demonstrated
anaplastic astrocytoma. Because the tumour involved the
cranial nerves and invaded the brainstem, aggressive
debulking was deferred and the patient was referred for
SRS. With the exception of hearing loss on the right, he
was neurologically intact. Chemotherapy was given
consisting of BCNU, thalidomide, imatinib meslate and
temozolamide. The tumour was treated with 19 Gy
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Table II. Results by tumour type as a function of tumour regression and survival
Tumour type Result
Pilocytic astrocytoma Tumour regression was seen in two of three patients after 26 months and tumour stability in the third after one month
without any change in neurological status.
Anaplastic astrocytoma Tumour regression without neurological change was achieved in one of these patients after 19 months (Figure 2).
Asymptomatic radionecrosis with tumour regression was observed in the second patient. 
Ependymoma Tumour recurrence was seen in the first patient before he was lost to follow-up. The other two patients died due to
tumour progression at six and seven months post-treatment.
Medulloblastoma Two of these patients with discrete lesions are stable at 25 and seven months post-treatment. The third child (Figure 3)
had a complete response initially but a small recurrent nodule was treated 11 months after the initial treatment. The
fourth child died 16 months post-treatment. 
PNET The child with a PNET died of diffuse recurrence at nine months post-treatment. 
Craniopharyngioma Tumour regression without visual changes was achieved in all three patients at 29, 39 and 40 months post-treatment. 
Rhabdoid tumour The right cerebellar nodule treated in the first of these patients is stable 28 months following treatment, but treatment
of a left cerebellar nodule resulted in symptomatic radionecrosis. The patient is improving and the MRI changes are
resolving (Figure 4 illustrates this dramatic result). Asymptomatic radionecrosis with tumor regression developed in the
second patient whose PET scan did not show hypermetabolic activity. The third patient died seven months post-
treatment from tumour progression.
Pineoblastoma The patient died 14 months post-treatment due to distant tumour progression. 
Meckel’s cave meningioma The patient showed progression 12 months post-treatment. The tumour bed was retreated following surgical resection
because similar tumours in her spine had recurred with resection alone. 
delivered in five daily fractions (3.8 Gy per day) to the
55% isodose line (Figure 2). An MRI scan three years
after treatment showed a decrease in tumor size, and the
patient remained neurologically unchanged. 
As a second example case history, a seven-month
old girl underwent an occipital craniotomy for resection of
a posterior fossa medulloblastoma. Post-operative MRI
showed residual enhancement believed to be tumour.
She received chemotherapy consisting of cisplatin,
cyclophosphamide, etoposide and vincristine. She was
then treated with a hypofractionated regimen consisting
of 20 Gy delivered in five fractions of 4 Gy prescribed to
the 55% isodose line (Figure 3). Five months later, the
patient was neurologically unchanged and MRI scanning
showed that the tumour was smaller.
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Figure 2a
Figure 2b
Figure 2c
Figure 2. (a) Enhanced axial image of an 18-month old boy with
anaplastic astrocytoma: before radiosurgery. (b) Enhanced axial CT
image CyberKnife SRS treatment plan for patient showing the 55%
isodose line. (c) Enhanced axial MR image of same patient three years
post-treatment after 19 Gy delivered to the 55% isodose line in five
fractions
Figure 3a
Figure 3b
Figure 3. (a) Enhanced axial CT image of a seven-month old girl
with medulloblastoma before SRS showing the 55% isodose line.
(b) Enhanced axial MR image of the patient five months post-treatment
after 20 Gy delivered to the 55% isodose line in five fractions
Discussion 
It is difficult to draw conclusions regarding the response
rates for individual tumour types because of the very
small size of each of our patient groups. Nevertheless,
tumour responses were observed in each group. For
example, the patients with pilocytic astrocytoma and
anaplastic astrocytoma responded well to radiosurgery.
Our results were mixed for medulloblastoma, with two
patients responding well and two showing tumor
progression. Long-term control was achieved in all three
patients with craniopharyngioma, although our fractio-
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Figure 4e Figure 4f
Figure 4c
Figure 4d
Figure 4a Figure 4b
Figure 4. (a) Enhanced axial CT image of a nine-month old girl with a residual nodule following resection of an atypical teratoid-rhabdoid tumor. The
nodule had progressed in size following resection. The 65% isodose line is shown. (b) Enhanced axial MR image four months post-treatment with
chemotherapy and 16.5 Gy prescribed to the 65% isodose line in one fraction. The nodule is smaller. (c) Enhanced axial MR image 19 months after SRS
showing development of a contralateral nodule. (d) Enhanced axial CT image showing the second treatment plan to treat the resection bed (after
resection of the contralateral nodule) with 24 Gy prescribed to the 60% isodose line (shown as the yellow curve) in four fractions. (e) Enhanced axial
MR image showing diffuse enhancement in the brain stem seven months after the second SRS treatment. The patient was sent for hospice care.
(f) Enhanced axial MR image showing resolution of enhancement 13 months after the second SRS. The clinical symptoms had markedly improved
nation schedule in these cases is better described as
stereotactic radiotherapy (SRT) than SRS [41, 42]. 
Our experience with rhabdoid tumours suggests that
aggressive radiosurgical treatment can contribute to
tumour control, but it is still too early to say whether the
results are durable. The three patients with ependymoma
all experienced poor results. This is in agreement with
other reports [15]. Finally, the failure of radiosurgery in
our patients with PNET and pineoblastoma is further
testimony that SRS treatment is ineffective against diffuse
disease.
These results should be viewed in light of the
aggressive nature of the treated tumours. A total of 20/21
patients had a surgical resection in their course, with
12/21 having had more than one resection. Also, 16/21
had received chemotherapy and 10/21 conventional
radiotherapy, whereas 3/21 had previously received
Gamma Knife SRS.
In terms of radiation doses, because the tumours in
our population were aggressive and because many of our
patients were referred after failure of other modalities,
our dose schedules tended to be aggressive. This can be
seen in our mean dose of almost 19 Gy and our use of
single-shot SRS regimens in 71% (27/38) of the treatment
plans.
The only toxicity seen was in the four children who
developed radionecrosis and who received deliberately
aggressive treatment plans because of otherwise dismal
prognosis. Because rhabdoid tumours are notoriously
aggressive [43] the first of these patients was initially
treated with both resection and chemotherapy, and
radiotherapy was withheld because of her young age.
Although a residual cerebellar nodule is stable 28 months
following SRS, she developed symptomatic radionecrosis
in the region of a second contralateral nodule that had
been treated with resection and a second SRS. However,
11 months later both the symptoms and radiological
findings are resolving (Figure 4). Our second patient with
a rhabdoid tumour was also treated with an aggressive
dose, resulting in asymptomatic biopsy proven radio-
necrosis 11 months after his initial treatment. He has also
received chemotherapy and underwent two surgical
resections.
One of our patients with an anaplastic astrocytoma
had developed a local recurrence after three surgical
resections, radiotherapy, a Gamma Knife SRS treatment
and chemotherapy. The most recent follow-up results,
18 months after his initial CyberKnife SRS demonstrated
that he is clinically stable, but has developed asympto-
matic radionecrosis. 
An anaplastic ependymoma patient also failed locally
after five surgical resections, radiotherapy, Gamma Knife
SRS and chemotherapy. He remained stable with radio-
logical findings of radionecrosis, but has unfortunately
been lost to follow-up after 10 months. 
Finally, use of the CyberKnife allowed avoidance of
anaesthesia in 8/21 patients. Rather surprisingly, patients
as young as five years old did not require anaesthesia.
Conclusions
The advantages of CyberKnife SRS for the paediatric
population include the ability to treat infants and younger
children. The increased comfort of a frameless system,
permits the opportunity to offer hypofractionated regi-
mens and a reduced requirement for general anaesthesia.
These advantages are particularly important for children
because of the malignant nature of their tumours and
the frequency of settings better suited for hypofractio-
nation than single-shot SRS. The feasibility of CyberKnife
SRS in infants has been proven, preliminary reports in
a relatively large population have been reported, and we
believe that CyberKnife SRS will become an invaluable
tool for the treatment of these serious tumours in young
patients.
Cole A. Giller MD, PhD
Baylor Radiosurgery Center
Baylor University Medical Center
3500 Gaston Avenue
Hoblitzelle 1
Dallas, TX 75246
USA
References
1. Duffner PK, Horowitz ME, Krischer JP et al. Postoperative chemotherapy
and delayed radiation in children less than three years of age with
malignant brain tumors. N Engl J Med 1993; 328: 1725-31.
2. Ries LAG, Smith MA, Gurney JG et al. (eds.). Cancer incidence and
survival among children and adolescents. United States SEER program
1975-1995, National Cancer Institute. NIH pub No 99-4649. Bethesda:
National Institutes of Health, 1999.
3. Hoppe-Hirsch E, Brunet L, Laroussinie F et al. Intellectual outcome
in children with malignant tumors of the posterior fossa: influence
of the field of irradiation and quality of surgery. Child’s Nerv Syst 1995; 11:
340-6.
4. Inoue HK, Kohga H, Nakamura M et al. Long-term follow-up study of
conventional irradiation for brain tumours in children: a role for
radiosurgery. Acta Neurochir 1994; 62 suppl: 83-8. 
5. Mostow EN, Byrne J, Connelly RR et al. Quality of long-term survivors of
CNS tumors of childhood and adolescence. J Clin Oncol 1991; 9: 592-9.
6. Walter AW, Mulhern RK, Gajjar A et al. Survival and neurode-
velopmental outcome of young children with medulloblastoma at St.
Jude Children’s Research Hospital. J Clin Oncol 1999; 17: 3720-8.
7. Baumann GS, Wara WM, Larson DA et al. Gamma Knife radiosurgery in
children. Pediatr Neurosurg 1996; 24: 193-201.
8. Colombo F, Benedetti A, Casentini L et al. Stereotactic radiosurgery of
intracranial tumors in children. J Neurosurg Sci 1985; 29: 233-7.
9. Eder HG, Leber KA, Eustacchio S et al. The role of Gamma Knife
radiosurgery in children. Child’s Nerv Syst 2001; 17: 341-6.
10. Gerszten PC, Adelson PD, Kondziolka D et al. Seizure outcome in
children treated for arteriovenous malformations using Gamma Knife
radiosurgery. Pediatr Neurosurg 1996; 24:139-44.
11. Grabb, PA, Lunsford LD, Albright AL et al. Stereotactic radiosurgery
for glial neoplasms of childhood. Neurosurgery 1996; 38: 696-702.
12. Hodgson DC, Goumnerova LC, Loeffler JS et al. Radiosurgery in the
management of pediatric brain tumors. Int J Radiat Oncol Biol Phys 2001;
50: 929-35.
13. Kondziolka D, Lunsford LD, Flickinger JC. Stereotactic radiosurgery in
children and adolescents. Pediatr Neurosurg 1990-1991; 16: 219-21.
14. Somaza SC, Kondziolka D, Lunsford LD et al. Early outcomes after
stereotactic radiosurgery for growing pilocytic astrocytomas in children.
Pediatr Neurosurg 1996; 25: 109-115.
7
15. Aggarwal R, Yeung D, Kumar P et al. Efficacy and feasibility of
stereotactic radiosurgery in the primary management of unfavorable
pediatric ependymoma. Radiother Oncol 1997; 43: 269-73.
16. Benk V, Clark BG, Souhami L et al. Stereotactic radiation in primary
brain tumors in children and adults Pediatr Neurosurg 1999; 31: 59-64.
17. Dunbar SF, Tarbell NJ, Kooy HM et al. Stereotactic radiotherapy for
pediatric and adult brain tumors: preliminary report. Int J Radiat Oncol
Biol Phys 1994; 30: 531-9.
18. Freeman CR, Souhami L, Caron JL et al. Stereotactic external beam
irradiation in previously untreated brain tumors in children and
adolescents. Med Pediatr Oncol 1994: 22: 173-80.
19. Hirth A, Pedersen P-H, Baardsen R et al. Gamma Knife radiosurgery
in pediatric cerebral and skull base tumors. Med Pediatr Oncol 2003: 40:
99-103.
20. Jawahar A, Kondziolka D, Flickinger JC et al. Adjuvant stereotactic
radiosurgery for anaplastic ependymoma. Stereotact Funct Neurosurg
1999: 73: 23-30.
21. Levy EI, Niranjan A, Thompson TP et al. Radiosurgery for childhood
intracranial arteriovenous malformations. Neurosurgery 2000: 47: 834-41.
22. Loeffler JS, Rossitch E, Siddon R et al. Role of stereotactic radiosurgery
with a linear accelerator in treatment of intracranial arteriovenous
malformations and tumors in children. Pediatrics 1990: 85: 774-82.
23. Patrice S, Tarbell NJ, Goumnerova LC et al. Results of radiosurgery in the
management of recurrent and residual medulloblastoma. Pediatr
Neurosurg 1995: 22: 197-203.
24. Raco A, Raimondi AJ, D’Alonzo A et al. Radiosurgery in the
management of pediatric brain tumors. Child’s Nerv Syst 2000: 16: 287-95.
25. Suh JH, Barnett GH. Stereotactic radiosurgery for brain tumors in
pediatric patients. Technol Cancer Res Treat 2003: 2: 141-6.
26. Weprin BE, Hall WA, Cho KH et al. Stereotactic radiosurgery in pediatric
patients. Pediatr Neurol 1996: 15: 193-9.
27. Zissiadis Y, Dutton S, Kieran M et al. Stereotactic radiotherapy for
pediatric intracranial germ cell tumors. Int J Radiat Oncol Biol Phys 2001:
51: 108-12.
28. Baker KC, Isert PR. Anaesthetic considerations for children undergoing
stereotactic radiosurgery. Anaesth Intens Care 1997; 25: 691-5.
29. Stokes MA, Soriano SG, Tarbell NJ et al. Anesthesia for stereotactic
radiosurgery in children. J Neurosurg Anesthesiol 1995; 7: 100-8.
30. Greitz T, Bergstrom M, Boethius J et al. Head fixation system for
integration of radiodiagnostic and therapeutic procedures. Neuroradiology
1980; 19: 1-6.
31. Kingsley DPE, Bergstrom M, Berggren BM. A critical evaluation of two
methods of head fixation. Neuroradiology 1980; 19: 7-12.
32. Hariz MI. Clinical study on the accuracy of the Laitinen CT-guidance
system in functional stereotactic neurosurgery. Stereotact Funct Neurosurg
1991; 56: 109-28.
33. Hariz MI, Henriksson R, Lofroth PO et al. A non-invasive method for
fractionated stereotactic irradiation of brain tumors with linear
accelerator. Radiother Oncol 1990; 17: 57-72.
34. Kooy HM, Dunbar SF, Tarbell NJ et al. Adaptation and verification of the
relocatable Gill-Thomas-Cosman frame in stereotactic radiotherapy. Int J
Radiat Oncol Biol Phys 1994; 30: 685-91.
35. Adler JR, Murphy MJ, Chang SD et al. Image-guided robotic
radiosurgery. Neurosurgery 1999: 44: 1299-1307. 
36. Chang SD, Main W, Martin DP et al. An analysis of the accuracy of the
CyberKnife: a robotic frameless stereotactic radiosurgical system.
Neurosurgery 2003; 52: 140-147.
37. Giller CA, Berger B, Gilio JP et al. Feasibility of radiosurgery for
malignant brain tumors in infants using image-guided robotic
radiosurgery: preliminary report. Neurosurgery 2004; 55: 916-25.
38. Giller CA, Berger BD, Pistenmaa DA et al. Robotically guided
radiosurgery for children. Pediatr Blood Cancer 2005; 44: 1-7. 
39. Smyth MD, Sneed PK, Ciricillo SF et al. Stereotactic radiosurgery for
pediatric intracranial arteriovenous malformations: the University of
California at San Francisco experience. J Neurosurg 2002: 97: 48-55.
40. Tanaka T, Kobayashi T, Kida Y et al. Comparison between adult and
pediatric arteriovenous malformations treated by Gamma Knife
radiosurgery. Stereotact Funct Neurosurg 1996: 66 suppl 1: 288-95.
41. Kalapurakal JA, Kepka A, Bista T et al. Fractionated stereotactic
radiotherapy for pediatric brain tumors: the Chicago children’s experience.
Child’s Nerv Syst 2000: 16: 296-300.
42. Saran FH, Baumert BG, Khoo VS et al. Stereotactically guided conformal
radiotherapy for progressive low-grade gliomas of childhood. Int J Radiat
Oncol Biol Phys 2002: 53: 43-51.
43. Packer RJ, Biegel JA, Blaney S et al. Atypical teratoid-rhabdoid tumor of
the central nervous system: report on workshop. J Pediatr Hematol Oncol
2002: 24: 337-42.
Paper received and accepted: 2 January 2006
8
